Welcome to our dedicated page for G1 Therapeutics news (Ticker: GTHX), a resource for investors and traders seeking the latest updates and insights on G1 Therapeutics stock.
G1 Therapeutics, Inc. (Nasdaq: GTHX) is a commercial-stage oncology biopharmaceutical company committed to developing next-generation therapies to improve the lives of cancer patients. The company is based in Research Triangle Park, N.C., and leverages its proprietary kinase drug discovery platform to advance a pipeline of innovative compounds. G1's flagship product, COSELA® (trilaciclib), has been approved by the FDA to decrease the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer (ES-SCLC).
In addition to COSELA, G1 Therapeutics is actively developing and evaluating trilaciclib in combination with other anti-cancer therapies. One notable project is the global, multi-center, randomized, placebo-controlled Phase 3 trial known as PRESERVE 2, which investigates trilaciclib in patients with metastatic triple-negative breast cancer (mTNBC). Preliminary results have shown promising survival benefits, indicating trilaciclib’s potential to protect bone marrow and enhance patient outcomes during cytotoxic therapy.
The company also engages in strategic partnerships to broaden its impact. For instance, G1 Therapeutics has entered agreements with companies like Pepper Bio and Jupiter Bioventures to advance the clinical development and commercialization of lerociclib, another promising CDK4/6 inhibitor. These collaborations aim to explore lerociclib's efficacy in treating various cancers, including HCC and radioprotection uses.
On the financial front, G1 Therapeutics reported revenues of $82.5 million for the full year 2023, reflecting significant growth from $51.3 million in the previous year. The company's ongoing commitment to innovation and strategic collaborations underscores its role as a key player in oncology therapeutics.
For more information, visit G1 Therapeutics and follow them on Twitter and LinkedIn.
G1 Therapeutics, Inc. (Nasdaq: GTHX) announced the grant of stock options totaling 320,600 shares to 31 employees on February 1, 2022. This includes 166,700 shares under the 2021 Inducement Equity Incentive Plan and 153,900 shares under the 2021 Sales Force Inducement Equity Incentive Plan. The options are granted at an exercise price of $10.34 per share, the closing price on the grant date. They vest over four years, beginning with a 25% vesting on the first anniversary. This move aims to attract talent and incentivize new employees, conforming to Nasdaq Listing Rule 5635.
G1 Therapeutics (Nasdaq: GTHX), an oncology-focused biopharmaceutical company, announces participation in two virtual investor conferences in January 2022. CEO Jack Bailey and CMO Raj Malik will engage in a fireside chat at the H.C. Wainwright BioConnect 2022 conference on January 10 at 7:00 AM EST. Bailey will present on January 12 at 1:30 PM EST during the 40th Annual J.P. Morgan Healthcare Conference. Webcasts for both events will be available on the company's website.
On January 3, 2022, G1 Therapeutics (GTHX) announced the grant of stock options totaling 65,200 shares to ten new employees as part of their Inducement Equity Incentive Plan. These stock options are intended to incentivize new hires, with an exercise price of $10.69 per share, equivalent to the company’s closing stock price on the grant date. Vesting occurs over four years, starting with 25% after one year of employment. G1 Therapeutics specializes in oncology treatments, including its commercial product COSELA™ and various clinical trials targeting multiple solid tumors.
G1 Therapeutics (GTHX) announced the end of its co-promotion agreement with Boehringer Ingelheim for COSELA, effective March 2022. The company plans to expand its oncology sales team by hiring 20 additional salespeople, raising the total to 34, to enhance sales activities and adoption of COSELA, which was FDA approved in February 2021. G1 will work with Boehringer Ingelheim on transitioning promotional efforts until March 2022, with reduced payments based on net sales of COSELA until March 2024. A webcast is scheduled to discuss these developments.
G1 Therapeutics (GTHX) announced the grant of stock options for a total of 158,100 shares to employees under its Inducement Equity Incentive Plans. This includes 101,700 shares under the Inducement Plan and 56,400 shares under the Sales Force Inducement Plan. The options are priced at $12.51 and have a ten-year term, vesting over four years. These grants aim to attract new talent to the company, aligning with Nasdaq Listing Rule requirements.
G1 Therapeutics has initiated a Phase 2 clinical trial of *trilaciclib* in patients with early-stage triple-negative breast cancer (TNBC). This open-label study aims to explore the drug's immune-modulating effects and assess pathologic complete response endpoints. With approximately 30 patients expected to enroll, initial results are anticipated in the second half of 2022. The trial highlights promising data from earlier studies, suggesting that trilaciclib may enhance tumor response and patient survival.
G1 Therapeutics has initiated a Phase 2 study of trilaciclib combined with Trodelvy® for the treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). The trial aims to assess the anti-tumor efficacy and myeloprotection of trilaciclib, with initial results expected in late 2022. Approximately 40 patients will be enrolled, focusing on those who have received at least two prior treatments. The primary endpoint is progression-free survival, while secondary endpoints include overall survival and myeloprotective effects.
G1 Therapeutics announced significant immunologic findings from their Phase 2 trial on metastatic triple-negative breast cancer (mTNBC), highlighting that trilaciclib enhances CD4 and CD8 T cell function when administered before chemotherapy. Patients receiving trilaciclib showed improved T cell responses and fewer immune-suppressing myeloid-derived suppressor cells compared to placebo. This research aims to deepen the understanding of the immune mechanisms behind improved survival rates observed in previous studies. Results were presented at the Society for Immunotherapy of Cancer's annual meeting.
On November 10, 2021, G1 Therapeutics (GTHX) announced participation in two virtual investor conferences. CEO Jack Bailey will present on November 17 at 8:00 AM EST at the Stifel 2021 Virtual Healthcare Conference. Additionally, he will engage in a fireside chat on December 1 at 12:35 PM EST during the 4th Annual Evercore ISI HealthCONx Conference. Both events will be webstreamed, accessible through the company's website. G1 Therapeutics focuses on developing cancer therapies, including its commercial product COSELA™.
G1 Therapeutics (GTHX) reported $4.9 million in total revenue for Q3 2021, including $3.6 million from COSELA sales. The company has announced a supplemental sales force to enhance COSELA adoption, alongside the publication of a permanent J-code for billing. G1 plans to initiate two new Phase 2 trials in Q4 2021 to further explore trilaciclib’s immune-based action. An amended debt facility now extends its cash runway into 2024, with cash and equivalents totaling $212.1 million at quarter-end. However, Q3 net loss widened to $42.5 million from $11.7 million year-over-year.
FAQ
What is the current stock price of G1 Therapeutics (GTHX)?
What is the market cap of G1 Therapeutics (GTHX)?
What does G1 Therapeutics, Inc. specialize in?
What is COSELA® (trilaciclib)?
What is the PRESERVE 2 trial?
Where is G1 Therapeutics, Inc. located?
Who are G1 Therapeutics' key partners?
What recent financial achievements has G1 Therapeutics reported?
What is lerociclib?
How can I get more information about G1 Therapeutics?
What types of cancer are G1 Therapeutics’ therapies targeting?
What are G1 Therapeutics’ future goals?
